https://scholars.lib.ntu.edu.tw/handle/123456789/592100
標題: | T helper type 17 in psoriasis: From basic immunology to clinical practice | 作者: | HSIEN-YI CHIU Cheng Y.-P. TSEN-FANG TSAI |
公開日期: | 2012 | 卷: | 30 | 期: | 4 | 起(迄)頁: | 136-141 | 來源出版物: | Dermatologica Sinica | 摘要: | Psoriasis is a chronic inflammatory disease mediated by a complex interplay between immune system and keratinocytes. Initially considered as a keratinocyte proliferation/differentiation disorder, an immune dysregulation was confirmed after the successful treatment of psoriasis with cyclosporine. The ying-yang theory, or T helper type 1 (Th1)/Th2 concept, was then introduced to explain the rarity of atopic dermatitis in patients with psoriasis and the aggravation of psoriasis after interferon-γ treatment. However, recent advances have revised the Th1/Th2 paradigm after the discovery of a novel subset of T cells, called Th17 cells. Th17 cells produce interleukin (IL)-17 and IL-22, and have other important downstream proinflammatory effects on skin, leading to clinical and pathological features typical of psoriasis. Nowadays, emerging evidence suggests integrative and complicated inflammatory circuits among Th1 and Th17 cells and keratinocytes in the pathogenesis of psoriasis, with Th17 cells playing a central role. Herein, we review the biology of Th17 cells as well as the reciprocal interplay between Th17 and regulatory T cells in psoriasis. Integration of the IL-23/Th17 axis into a revised concept of psoriasis has already been translated into novel therapeutic strategies. Studies investigating the effect and molecular mechanism of conventional and biological therapy for psoriasis on the IL-23/Th17 pathway were also discussed. ? 2012, Taiwanese Dermatological Association. Published by Elsevier Taiwan LLC. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84870888397&doi=10.1016%2fj.dsi.2012.08.002&partnerID=40&md5=ee5d6be08dce3ec54636acfeccf506d4 https://scholars.lib.ntu.edu.tw/handle/123456789/592100 |
ISSN: | 1027-8117 | DOI: | 10.1016/j.dsi.2012.08.002 | SDG/關鍵字: | brodalumab; cyclosporin A; etanercept; etretin; infliximab; interleukin 12 antibody; interleukin 23; interleukin 23 antibody; ixekizumab; methotrexate; placebo; secukinumab; tumor necrosis factor; tumor necrosis factor alpha inhibitor; tumor necrosis factor inhibitor; ustekinumab; cardiovascular disease; cell differentiation; clinical practice; cytokine production; drug activity; drug efficacy; drug response; drug safety; drug withdrawal; human; immune response; infection; latent tuberculosis; nonhuman; pathogenesis; psoriasis; regulatory T lymphocyte; review; skin cancer; Th17 cell |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。